iHuman Inc. (NYSE:IH - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 4,300 shares, a decrease of 71.1% from the March 31st total of 14,900 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily trading volume, of 78,000 shares, the days-to-cover ratio is presently 0.1 days.
Institutional Trading of iHuman
A hedge fund recently raised its stake in iHuman stock. Citadel Advisors LLC raised its stake in shares of iHuman Inc. (NYSE:IH - Free Report) by 24.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,683 shares of the company's stock after buying an additional 9,314 shares during the quarter. Citadel Advisors LLC owned about 0.09% of iHuman worth $81,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 4.92% of the company's stock.
iHuman Trading Up 4.3 %
IH traded up $0.09 during midday trading on Friday, reaching $2.17. The company's stock had a trading volume of 10,395 shares, compared to its average volume of 42,504. The firm has a market capitalization of $113.32 million, a price-to-earnings ratio of 7.75 and a beta of 0.33. The stock's 50-day moving average is $2.18 and its 200-day moving average is $1.88. iHuman has a 1 year low of $1.47 and a 1 year high of $3.18.
iHuman (NYSE:IH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 25th. The company reported $0.07 earnings per share (EPS) for the quarter. The firm had revenue of $31.88 million for the quarter. iHuman had a return on equity of 11.29% and a net margin of 11.22%.
iHuman Announces Dividend
The company also recently announced a -- dividend, which will be paid on Thursday, May 15th. Shareholders of record on Thursday, April 17th will be paid a dividend of $0.10 per share. The ex-dividend date of this dividend is Thursday, April 17th.
iHuman Company Profile
(
Get Free Report)
iHuman Inc provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Writing, iHuman Fantastic Friends, and iHuman Readers; bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy, and Gogo Town; and Aha World, an open-ended interactive app that nurtures a desire for discovery.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iHuman, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iHuman wasn't on the list.
While iHuman currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.